DeGruttola V - Search Results

1

Fleming TR, DeGruttola V, DeMets DL. Fleming TR, et al. Among authors: degruttola v. AIDS Clin Rev. 1997-1998:129-43. AIDS Clin Rev. 1997. PMID: 9305447 Review. No abstract available.

2

Estimating the proportion of treatment effect explained by a surrogate marker.

Lin DY, Fleming TR, De Gruttola V. Lin DY, et al. Stat Med. 1997 Jul 15;16(13):1515-27. doi: 10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1. Stat Med. 1997. PMID: 9249922

3

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. De Gruttola VG, et al. Control Clin Trials. 2001 Oct;22(5):485-502. doi: 10.1016/s0197-2456(01)00153-2. Control Clin Trials. 2001. PMID: 11578783

4

Perspective: validating surrogate markers--are we being naive?

De Gruttola V, Fleming T, Lin DY, Coombs R. De Gruttola V, et al. J Infect Dis. 1997 Feb;175(2):237-46. doi: 10.1093/infdis/175.2.237. J Infect Dis. 1997. PMID: 9203643 Review.

5

Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.

Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, Fleming TR, Halloran ME, Horby P, Jaki T, Krause PR, Longini IM, Mulangu S, Muyembe-Tamfum JJ, Nason MC, Smith PG, Wang R, Henao-Restrepo AM, De Gruttola V. Dean NE, et al. N Engl J Med. 2020 Apr 2;382(14):1366-1369. doi: 10.1056/NEJMsb1905390. N Engl J Med. 2020. PMID: 32242365 Free PMC article. No abstract available.

6

COVID-19 vaccine trials should seek worthwhile efficacy.

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R; World Health Organization Solidarity Vaccines Trial Expert Group. Krause P, et al. Lancet. 2020 Sep 12;396(10253):741-743. doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27. Lancet. 2020. PMID: 32861315 Free PMC article. No abstract available.

7

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Fleming TR, DeGruttola V, Donnell D. Fleming TR, et al. Among authors: degruttola v. Stat Commun Infect Dis. 2019;11(1):20190001. doi: 10.1515/scid-2019-0001. Epub 2019 Jul 18. Stat Commun Infect Dis. 2019. PMID: 33777327 Free PMC article.

8

Viral load and response to treatment of HIV.

De Gruttola V, Fleming T, Coombs R. De Gruttola V, et al. N Engl J Med. 1996 Jun 20;334(25):1671-2; author reply 1672-3. N Engl J Med. 1996. PMID: 8628373 No abstract available.

9

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

10

A flexible B-spline model for multiple longitudinal biomarkers and survival.

Brown ER, Ibrahim JG, DeGruttola V. Brown ER, et al. Among authors: degruttola v. Biometrics. 2005 Mar;61(1):64-73. doi: 10.1111/j.0006-341X.2005.030929.x. Biometrics. 2005. PMID: 15737079

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page